- Home
- ABEO vs LXEO Comparison
ABEO vs LXEO Comparison
Compare ABEO & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | LXEO |
|---|---|---|
| Founded | 1974 | 2017 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 396.5M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ABEO | LXEO |
|---|---|---|
| Price | $7.07 | $4.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.00 | $18.44 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | $654,000.00 |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $3.60 |
| 52 Week High | $7.54 | $10.99 |
Technical Indicators
Market Signals| Indicator | ABEO | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 47.08 |
| Support Level | $4.85 | $4.27 |
| Resistance Level | N/A | $5.34 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 91.07 | 34.29 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.